Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma

Bookmark and Share
Published: 11 Apr 2019
Views: 1158
Prof Sandip Patel - UC San Diego, San Diego, USA

Prof Sandip Patel gives a press conference at AACR 2019 on results from the DART phase II trial which showed the combination of ipilimumab and nivolumab to have clinical benefit when treating high-grade neuroendocrine carcinoma.